

# Analysis of Complement Receptor Type 1 (CR1) Polymorphisms and Its Association With Malaria in Rural Population of Maharashtra

Kanchan Mahadik, Roshan Shaikh, Namrata Mahajan, Aarti Pandit, Shivam Shinde, Kanjaksha Ghosh, Ajit C. Gorakshakar

**Abstract—** The interaction between human host and the *Plasmodium* parasite is complex. The factors affecting the causality of infection and its severity are yet not completely understood. Single Nucleotide Polymorphisms (SNP) associated with CR1 may be associated with patho-physiology of malaria and its susceptibility to the disease. **Methods:** The objective of the present study was to calculate the incidence of various antigens of Knops blood group system and CR1 Exon22 polymorphisms in rural population from Chiplun Taluka of Ratnagiri district. The study included 112 malaria positive cases and 909 healthy controls, which were screened for CR1 Exon22 polymorphism. Knops (Kna/b), McCoy (McCa/b), Swain-Langley (SI1/2) polymorphisms were screened in 93 cases and 321 healthy controls. The frequencies were determined using a PCR-RFLP technique. **Results:** Only wild types of the allele form were observed in Knops blood group system in malaria cases and healthy control. CR1 exon22 polymorphism was seen in the study population with all the 3 allele type distributed in the cases and control samples. No significant allelic or genotypic differences were found between the controls and the disease groups. **Conclusion:** The results of the present study demonstrate that common CR1 Exon22 and Knops blood group system are not associated with malaria in the endemic area.

**Index Terms—** Complement receptor 1, Knops, McCoy, Swain-Langley, Malaria, Single Nucleotide polymorphisms (SNP), PCR-RFLP..

## I. INTRODUCTION

Malaria is a widespread parasitic disease of humans. It can be caused by any of the four species of *Plasmodium*, of which *Plasmodium falciparum* is responsible for most of the cases of the disease and death across sub Sahara Africa, while *Plasmodium vivax* is the most prevalent parasite in other parts of the World [1]. According to WHO, there were about 198 million cases of malaria in 2013 and an estimated 5,84,000 deaths [2]. Even with significant decrease in malaria related mortality and morbidity, the disease still poses huge risk to humans.

Kanchan Mahadik<sup>1</sup>, Roshan Shaikh<sup>1</sup>, Namrata Mahajan<sup>2</sup>, Ajit C. Gorakshakar, Department of Transfusion medicine, National Institute of Immunohaematology, New Multistoreyed Bldg, KEM Hospital Campus, Parel, Mumbai 400012, India

Aarti Pandit, Taluka Health Officer, Chiplun, Ratnagiri  
Shivam Shinde, Medical Officer, Primary Health Centre, Kapre, Chiplun, Ratnagiri

Kanjaksha Ghosh, Director, Surat Raktadan Kendra & Research Centre, Regional Blood Transfusion Centre, Udhana - Magdalla Road, Surat - 394

Several groups are engaged in determining the factors that lead to the development of malaria. The main factors that are being focused in research are parasite virulence phenotypes and host genetic factors. There is a complex interaction between host-parasite and the factors that influence severity of disease are still not fully understood. With little effect implicated by the environment, the primary factors that are involved, are that of the genomes of host and parasite. It is believed that the formation of rosette [3] is associated with the malaria pathology via obstruction in smaller capillaries [4-6]. Rosetting is mediated by the parasite ligand, *P. falciparum* erythrocyte membrane protein 1 (PfEMP1) on the surface of infected RBCs, which binds to various molecules like complement receptor 1 (CR1/ CD35) [7] and blood groups antigens [8]. The human C3b/C4b receptor (CR1) is present on the surface of erythrocytes, polymorphonuclear leukocytes, monocytes/macrophages, B lymphocytes, some T lymphocytes, follicular dendritic cells, and glomerular podocytes [9,10].

The major functions of CR1 as the receptor are: adherence to and removal of C3b- and C4b-containing immune complexes from the circulation, and regulation of the complement cascade to prevent autologous complement attack [11]. Several polymorphic traits of CR1 have been reported which result in variations in the number of C3b binding sites [12]. The gene encoding CR1 is located at long arm of chromosome 1 in humans. Studies showed that CR1 gene polymorphisms influence CR1 production or expression and are associated with malaria in several populations [13-15]. Clinical studies have showed a correlation between serum CR1 level and disease severity in patients with malaria [16-17]; few results were inconsistent [18-19]. National Center for Biotechnology Information SNP database showed that CR1 gene rs2274567 G/A, rs4844600 G/A, and rs2296160 C/T sites (all are located in coding region) have different frequencies of polymorphism distribution in different ethnic group. However, there have been very few studies to examine the association between SNPs of CR1 gene rs2274567 G/A with malaria in Indian population [20-22].

Several antigens have been described in the Knops blood group system which is a part of CR1 and this includes Knops antigens a/b (Kna/Knb), McCoy a/b (McCa/McCb), Swain-Langley 1/2 (SI1/SI2). The genetic polymorphisms that results in differential expression of these antigens are

# Analysis of Complement Receptor Type 1 (CR1) Polymorphisms and Its Association With Malaria in Rural Population of Maharashtra

related to the nucleotide change in the coding regions. The details of these polymorphisms and the associated changes are listed in the table [1].

Several groups have investigated the association between polymorphisms in the Knops blood group system and malaria. Moulds et al. in 2010 [23] described the molecular basis for McC and S1 allele. In the study, they determined the frequencies of these alleles in West Africa (pooled samples n= 182) and Malian Population (n=99). The allele frequencies were found to be 31% (McC<sup>b</sup>) and 79% (S12) in West African samples and 30% (McC<sup>b</sup>) and 76% (S12) from Mali. Later several groups have studied the association of Knops blood group and severe malaria, with inconsistent results [24-26].

The aim of the present study was to look for any possible association of various genetic markers with malaria infection. In the present publication we are presenting the data on antigens of Knops blood group system and CR1 Exon22 polymorphisms. The data obtained helped to calculate the incidence of various antigens of Knops blood group system and CR1 Exon22 polymorphisms in rural population from Chiplun Taluka of Ratnagiri district, Maharashtra.

## II. MATERIALS AND METHOD

### A. Ethics Statements:

The study and its protocols were approved by the Institutional Ethics Committee of National Institute of ImmunoHematology(NIIH-ICMR). Blood samples were collected after written consent of the healthy controls, and malaria patients.

### B. Study Site and Sample Collection:

The study was conducted at the Primary Health Centre (PHC) at Dadar, Ratnagiri, Maharashtra. Ratnagiri is one of the district of Konkan region from south west Maharashtra. Chiplun is one of the taluka of this district. North east part of this taluka is a hilly malaria endemic area. The primary Health Centre (PHC) at Dadar covers this area. About 15-20 villages are under the PHC (Figure1). Katkaris, Dhangars tribal groups and Kunbis are the three main ethnic group seen in this region.

Katkaris are nomadic, forest dwelling tribals, scattered in small groups staying in an area known as "padas". They are seen throughout the hill regions and forest of Ratnagiri, Raigad and Thane districts of Maharashtra. Dhangars, nomadic tribal groups, are traditionally being shepherds and buffalo keepers and live a socially isolated life, due to their occupation in forest or hills far away from the main village. Kunbis are cultivators and main rural population in the region.

During 2009-2011, more than 350 cases of malaria, of which 70-85% were caused due to *P vivax* were detected at Dadar PHC. Therefore in the present study, samples were collected from retrospective malaria positive cases and from normal healthy individuals, to screen for various genetic markers in malaria endemic area.

### C. DNA Isolation and Genotyping:

DNA was extracted from the lymphocyte by Phenol: CHCl<sub>3</sub> method. The lymphocytes were separated by preferential lysis of RBC and separation of lymphocytes by centrifugation. The extracted DNA was checked for its quality and quantity prior to PCR.




Figure1: Sample Collection Area in Chiplun

### D. Polymerase chain reaction:

All amplification reactions were carried out in a final volume of 25 $\mu$ l, which included 0.3 $\mu$ M of each primer (forward and reverse), dNTP at 200 $\mu$ M, 2.5mM MgCl<sub>2</sub> and 1 Unit of DNA polymerase (Bangalore Genei) with 1X Taq DNA polymerase buffer. Approximately 100ng DNA was used in the PCR reaction. Amplification conditions included an initial denaturation at 95 $^{\circ}$ C (5 min) and 34 cycles of denaturation at 95 $^{\circ}$ C (45 sec), annealing of primers to the templates at specified temperature (45 sec) and extension at 72 $^{\circ}$ C for 45 sec. A final extension step lasted for 5 min at 72 $^{\circ}$ C followed by 4 $^{\circ}$ C for 5 mins. 5 $\mu$ l of amplified PCR products from each amplification were run on a 1% agarose gel to check quality of amplification.

For CR1 Exon22 amplification, touch-down PCR (TD: 62-55 with -0.5 $^{\circ}$ C for 13 cycles and 25 cycles as conventional PCR with annealing at 55 $^{\circ}$ C) was employed to eliminate the non specific amplification and to increase the product yield.

Genetic variant of CR1 (A3650G RsaI) polymorphisms was determined by using PCR-RFLP technique (Table 1). DNA fragment containing the CR1 A3650G RsaI polymorphic site was amplified using primer sequences listed in the table. PCR

product of 682 bp also contains one non-polymorphic site for RsaI which cuts it into 520 bp and 162 bp fragments. In the presence of CR1 A3650G RsaI variant allele (G) 520 bp band was further cleaved into 458 and 62 bp, while the alternate allele (A) remained uncut.

Polymorphisms in Knops blood groups system were also assessed using PCR-RFLP. The polymorphism and the restriction enzyme utilized to detect the polymorphisms are listed in table2.

**Table1: CR1 and Knops Blood Group Antigen Polymorphisms**

| Antigen                      | rs No.   | Phenotype        | Nucleotide Position | Amino Acid Change |
|------------------------------|----------|------------------|---------------------|-------------------|
| Knops<br>(27)                | 41274768 | Kn <sup>a</sup>  | 4708                | V1561M            |
|                              |          | Kn <sup>b</sup>  |                     |                   |
| McCoy<br>(28)                | 17047660 | McC <sup>a</sup> | 4795                | K1590E            |
|                              |          | McC <sup>b</sup> |                     |                   |
| Swain-L<br>angley<br>(28,29) | 17047661 | Sl <sub>1</sub>  | 4828                | R1601G            |
|                              |          | Sl <sub>2</sub>  |                     |                   |
| CR1<br>Exon 22<br>(30,31)    | 2274567  |                  | 3650                | H1208R            |

**Table2: PCR specifications for Amplification of Target region**

| Antigen        | Primer Sequence (5'→3')                                      | Ta            | bp  | Restriction Enzymes |
|----------------|--|---------------|-----|---------------------|
| Knops          | FP: ACCAGTGCC<br>ACACTGGACCA<br>GATGGAGAACA<br>GCTGTT        | 57.3°C        | 305 | NdeI                |
| McCoy          | RP: TGAGCAT  |               |     | BsmI                |
| Swain-Langley  | FP: GGAGGAGTGTG<br>GCAGCTTG                                  |               |     | MfeI                |
| CR1<br>Exon 22 | FP: TTCACATGGAT<br>AGCCAGAGC<br>RP: CCAGAGGTAA<br>TCTCCCTGGA | TD<br>(62-55) | 682 | RsaI                |

### III. RESULTS AND DISCUSSION

We in this study analysed the genetic diversity of complement regulatory gene by examining the SNPs associated with Knops blood group antigens viz., Knops (a/b); McCoy (a/b) and Swain-Langley (1/2) along with polymorphism in CR Exon22 in the above mentioned population group.

Examination of the of the Malaria cases and Normal Healthy control yielded only wild type haplotype involving Knops, McCoy and Swain-Langley polymorphisms. A study (n=200) conducted by Monika et al. 2009 [32] showed that only wild type and homozygous mutant type allele is predominant in Indian population. Here in our study (n=414) we found only the wild type form of the Kn<sup>a+</sup>, McCoy<sup>a+</sup> and Sl1/1 alleles resulting in 100% of only one type allele of the antigen (Table-3).

CR1 Exon22 polymorphism was observed in the given subjects. However, the distribution of wild type (AA homozygous); heterozygous (A/G) and the mutant type (G/G) alleles of CR1 exon22 between malaria cases and their counter normals showed no difference in genotypic (Table4) or allelic (Table5) frequencies.

**Table3: Genotypic Frequency for Knops Blood Group Antigen**

| Genotypic Frequency |          |               |                  |                     |         |
|---------------------|----------|---------------|------------------|---------------------|---------|
| SNP                 | Genotype | Cases n=93(%) | Control n=321(%) | Odds ratio (95% CI) | P-value |
| Kna/b               | a/a      | 93 (100%)     | 321 (100%)       | NS                  | NS      |
|                     | a/b      | 0 (0%)        | 0 (0%)           | NS                  | NS      |
|                     | b/b      | 0 (0%)        | 0 (0%)           | NS                  | NS      |
| McCa/b              | a/a      | 93 (100%)     | 321 (100%)       | NS                  | NS      |
|                     | a/b      | 0 (0%)        | 0 (0%)           | NS                  | NS      |
|                     | b/b      | 0 (0%)        | 0 (0%)           | NS                  | NS      |
| Sl1/Sl2             | 1/1      | 93 (100%)     | 321 (100%)       | NS                  | NS      |
|                     | ½        | 0 (0%)        | 0 (0%)           | NS                  | NS      |
|                     | 2/2      | 0 (0%)        | 0 (0%)           | NS                  | NS      |

To assess the prevalence of CR1 polymorphism in exon 22 in studied population, 909 healthy controls were genotyped by PCR-RFLP and the results are shown in Table-4. For exon22 polymorphism, frequency of GG genotype was found to be 44% than AG which accounted for 41, while AA was seen only in 15% of the normal population. A study by Aditya et al [32] have demonstrated similar results (GG 44% AG 41% and AA15%). The distribution of exon22 genotypes in healthy controls was in agreement with HWE.

# Analysis of Complement Receptor Type 1 (CR1) Polymorphisms and Its Association With Malaria in Rural Population of Maharashtra

We used a case control study to examine whether polymorphism at CR1 gene is associated with malaria. The functional CR1 polymorphisms (exon22) in infected subjects were typed and results are shown in Table4. For the CR1 exon22 polymorphism in malaria cases, the frequency of the GG genotype was found to be 40%, AG 42%. Prevalence of homozygous wild type (AA) was lower (AA 18%).

**Table4: Genotypic Frequency for CR1 Exon22**

| Genotypic Frequency |          |                 |                   |                        |         |
|---------------------|----------|-----------------|-------------------|------------------------|---------|
| SNP                 | Genotype | Cases n=112 (%) | Control n=909 (%) | Odds ratio (95% CI)    | P-value |
| CR Exon 22          | A/A      | 45 (40.17)      | 352 (38.72)       | 1.0628 (0.712-1.5865)  | 0.7657  |
|                     | A/G      | 52 (46.42)      | 415 (45.65)       | 1.0316 (0.696-1.5292)  | 0.8767  |
|                     | G/G      | 15 (13.39)      | 142 (15.62)       | 0.8353 (0.4712-1.4807) | 0.5377  |

**Table4: Allelic Frequency for CR1 Exon22**

| Allelic Frequency |        |                |                    |                        |         |
|-------------------|--------|----------------|--------------------|------------------------|---------|
| SNP               | Allele | Cases n=224(%) | Control n=1818 (%) | Odds ratio (95% CI)    | P-value |
| CR22              | A      | 142 (63.39)    | 1119 (61.55)       | 1.0817 (0.8112-1.4425) | 0.5926  |
|                   | G      | 82 (36.6)      | 699 (38.44)        | 0.9244 (0.6932-1.2327) | 0.5926  |

## IV. CONCLUSIONS

The results from this study confirm earlier findings by Monika et al. 2009 [33]. Kna, McCa, and S11, being the only genotype found in the Indian population. Also Kn, McC and S1 do not seem to confer any protective advantage against malaria infection. Based on these findings, in a very well-characterized population, malaria does not seem to be the selective force on these alleles. Moulds et al [23] reported frequency of Knb in Bandiagara be 18.3%. Other serologic studies have reported that the frequency of Knb ranged from 1.2% among African American persons living in Philadelphia [34] to 4.7% among 63 random Caucasian donors [35]. Helle et al 2013 [36] compared the allele frequencies of McC and S1. In the comparison, it was found that the Ghanaian population differed significantly from the Gambian at the McC loci, having a lower frequency of the McCb allele ( $p < 0.001$ , 0.27 vs 0.39). The S1 loci in the Ghana differed from

both Mali ( $p = 0.02$ , 0.83 vs 0.76) and Kenya ( $p < 0.001$ , 0.83 vs 0.68) by a higher frequency of the S12 allele and slightly differed from The Gambia ( $p = 0.06$ , 0.83 vs 0.80).

The present study did not revealed any association between CR1 gene rs2274567 G/A polymorphisms and malaria in the selected tribal population. Nevertheless, further studies are needed to explore the complex interaction between environmental factors and CR1 gene polymorphisms in the risk of malaria, especially in ethnically disparate populations.

## COMPETING INTERESTS

The authors declare that they have no competing interests.

## AUTHORS' CONTRIBUTIONS

Aarti P. and Shivam S. helped in sample collection and organization of the blood collection camps in Chiplun Taluka, Ratnagiri, Kanchan M and Namrata M, carried out the laboratory work, Roshan S. analysed the data, supervised DNA work and wrote the manuscript. Ajit C. G. contributed to study design and interpretation of data, and revised the manuscript for important intellectual content. Kanjaksha Ghosh contributed to concept development and study design. All authors read and approved the final manuscript.

## ACKNOWLEDGMENT

We are grateful to all the participants of the Primary Health Centre (PHC) at Dadar, Ratnagiri and the patients and healthy controls who participated in the study. We are also thankful to M/s Jyoti C. Patel for helping us with the electropherograms and Indian Council of Medical research, New Delhi for funding.

## REFERENCES

- [1] Kappe SH, Vaughan AM, Boddey JA and Cowman AF. That was then but this is now: Malaria research in the time of an eradication agenda. *Science* 328:862-866, (2010).
- [2] WHO: World Malaria Report 2011. Geneva: World Health Organization; 2014.
- [3] David PH, Handunnetti SM, Leech JH, Gamage P, Mendis KN: Rosetting: a new cytoadherence property of malaria-infected erythrocytes. *Am J Trop Med Hyg.* 38:289-297, (1988).
- [4] Rowe A, Obeiro J, Newbold CI, Marsh K: Plasmodium falciparum rosetting
- [5] is associated with malaria severity in Kenya. *Infect Immun.* 63:2323-2326, (1995).
- [6] Rowe JA, Moulds JM, Newbold CI, Miller LH: P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. *Nature*, 388:292-295, (1997).
- [7] Carlson J, Helmby H, Hill AV, Brewster D, Greenwood BM, Wahlgren M: Human cerebral malaria: association with erythrocyte rosetting and lack of anti-rosetting antibodies. *Lancet.* 336:1457-1460, (1990).
- [8] Rowe JA, Moulds JM, Newbold CI, Miller LH. P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complementreceptor 1. *Nature* 388: 292-295, (1997).
- [9] Panda AK, Panda SK, Sahu AN, Tripathy R, Ravindran B, et al. Association of ABO blood group with severe falciparum malaria

- in adults: case control study and meta-analysis. *Malar J* 10: 309, (2011).
- [10] Fearon, D. T., and W. W. Wong. Complement ligand-receptor interactions that mediate biological responses. *Annu. Rev. Immunol.* 1:243, (1983).
- [11] Reynes, M., J. P. Aubert, J. H. M. Cohen, J. Audouin, V. Tricotet, J. Diebold, and M. D. Kazatchkine. Human follicular dendritic cells express CR1, CR2 and CR3 complement receptor antigens. *J. Immunol.* 135:2687, (1985).
- [12] Ahearn JM, Fearon DT: Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). *Adv Immunol*, 46:183–219, (1989).
- [13] Hourcade D, Miesner DR, Bee C, Zeldes W, Atkinson JP: Duplication and divergence of the amino-terminal coding region of the complement receptor 1 (CR1) gene. An example of concerted (horizontal) evolution within a gene. *J Biol Chem*, 265:974–980, (1990).
- [14] Cockburn IA, Mackinnon MJ, O'Donnell A, Allen SJ, Moulds JM, Baisor M, et al. A human complement receptor 1 polymorphism that reduces *Plasmodium falciparum* rosetting confers protection against severe malaria. *Proc Natl Acad Sci U S A*; 101:272-7, (2004).
- [15] Nagayasu E, Ito M, Akaki M, Nakano Y, Kimura M, Looareesuwan S, et al. CR1 density polymorphism on erythrocytes of falciparum malaria patients in Thailand. *Am J Trop Med Hyg*; 64: 1-5, (2001).
- [16] Rout R, Dhangadamajhi G, Mohapatra BN, Kar SK, Ranjit M. High CR1 level and related polymorphic variants are associated with cerebral malaria in eastern-India. *Infect Genet Evol*;11: 139-44, (2011).
- [17] Mahajan RC, Narain K, Mahanta J. Anaemia & expression levels of CD35, CD55 & CD59 on red blood cells in *Plasmodium falciparum* malaria patients from India. *Indian J Med Res*;133: 662-4, (2011).
- [18] Tham WH, Schmidt CQ, Hauhart RE, Guariento M, Tetteh-Quarcoo PB, Lopaticki S, et al. *Plasmodium falciparum* uses a key functional site in complement receptor type-1 for invasion of human erythrocytes. *Blood*;118:1923-33, (2011).
- [19] Soares SC, Abé-Sandes K, Nascimento Filho VB, Nunes FM, Silva WA Jr. Genetic polymorphisms in TLR4, CR1 and Duffy gene are not associated with malaria resistance in patients from Baixo Amazonas region, Brazil. *Genet Mol Res*;7:1011-9, (2008).
- [20] Rowe JA, Raza A, Diallo DA, Baby M, Poudiougou B, Coulibaly D, et al. Erythrocyte CR1 expression level does not correlate with a HindIII restriction fragment length polymorphism in Africans; implications for studies on malaria susceptibility. *Genes Immun*;3:497-500, (2002).
- [21] R Kosoy, M Ransom, H Chen, M Marconi, F Macciardi, N Glorioso, P K Gregersen, D Cusi and M F Seldin. Evidence for malaria selection of a CR1 haplotype in Sardinia *Genes and Immunity* 12, 582-588 (October 2011)
- [22] A Srivastava, B Mittal. Complement receptor 1 (A3650G RsaI and intron 27 HindIII) polymorphisms and risk of gallbladder cancer in north Indian population. *Scand. J. Immunol*, 70(6):614-20 (2009).
- [23] Ronnaly Rout, Gunanidhi Dhangadamajhi, Biranchi N Mohapatra, Shantanu K Kar, Manoranjan Ranjit. High CR1 level and related polymorphic variants are associated with cerebral malaria in eastern-India. *Infect. Genet. Evol.* 14;11(1):139-44 (2011).
- [24] J.M. Moulds, B.J. Thomas, O. Doumbo, D.A. Diallo, K.E. Lyke, C.V. Plowe, J.A. Rowe, and D.J. Birmingham, Identification of the Kna/Knb polymorphism and a method for
- [25] Knops genotyping *Transfusion.*; 44(2): 164–169 (2004)
- [26] Thathy V, Moulds JM, Guyah B, Otieno W, Stoute JA: Complement receptor1 polymorphisms associated with resistance to severe malaria in Kenya. *Malar J*, 4:54, (2005)
- [27] Zimmerman PA, Fitness J, Moulds JM, McNamara DT, Kasehagen LJ, Rowe JA, Hill AV: CR1 Knops blood group alleles are not associated with severe malaria in the Gambia. *Genes Immun*, 4:368–373, (2003).
- [28] Jallow M, Teo YY, Small KS, Rockett KA, Deloukas P, Clark TG, Kivinen K, Bojang KA, Conway DJ, Pinder M, Sirugo G, Sisay-Joof F, Usen S, Auburn S, Bumpstead SJ, Campino S, Coffey A, Dunham A, Fry AE, Green A, Gwilliam R, Hunt SE, Inouye M, Jeffreys AE, Mendy A, Palotie A, Potter S, Ragoussis J, Rogers J, Rowlands K, et al: Genome-wide and fine-resolution association analysis of malaria in West Africa. *Nat Genet*, 41:657–665, (2009).
- [29] Moulds JM, Thomas BJ, Doumbo O, Diallo DA, Lyke KE, Plowe CV, Rowe JA, Birmingham DJ: Identification of the Kna/Knb polymorphism and a method for Knops genotyping. *Transfusion*, 44:164–169 (2004).
- [30] Moulds JM, Zimmerman PA, Doumbo OK, Kassambara L, Sagara I, Diallo DA, Atkinson JP, Krych-Goldberg M, Hauhart RE, Hourcade DE, McNamara DT, Birmingham DJ, Rowe JA, Moulds JJ, Miller LH: Molecular identification of Knops blood group polymorphisms found in long homologous region D of complement receptor 1. *Blood*, 97:2879–2885 (2001).
- [31] Moulds JM, Zimmerman PA, Doumbo OK, Diallo DA, Atkinson JP, KrychGoldberg M, Hourcade DE, Moulds JJ: Expansion of the Knops blood group system and subdivision of SI(a). *Transfusion*, 42:251–256 (2002).
- [32] Cockburn IA, Mackinnon MJ, O'Donnell A, Allen SJ, Moulds JM, et al. A human complement receptor 1 polymorphism that reduces *Plasmodium falciparum* rosetting confers protection against severe malaria. *Proc Natl Acad Sci U S A* 101: 272–277 (2004).
- [33] Xiang L, Rundles JR, Hamilton DR, Wilson JG Quantitative alleles of CR1: coding sequence analysis and comparison of haplotypes in two ethnic groups. *J Immunol* 163: 4939–4945 (1999).
- [34] Aditya, Panda AK, Panda M, Tripathy R, Pattanaik SS, Ravindran B, et al. Complement Receptor 1 Variants Confer Protection from Severe Malaria in Odisha, India. *PLoS ONE* 7(11) (2012).
- [35] Monika et al. Role of CR1Knops polymorphism in the pathophysiology of malaria: Indian Scenario, *J Vector Borne Dis* 46, Dec 2009, pp. 288-294 (2009).
- [36] Molthan L. The serology of the York-Cost-McCoy-Knops red blood cell system. *Am J Med Technol*.49:49–56 (1983)
- [37] Mallan MT, Grimm W, Hindley L, et al. The Hall serum: detecting Knb, the antithetical allele toKna (Abstract). *Transfusion*.20:630 (1980).
- [38] Helle H Hansson I, Jørgen A Kurtzhals, Bamenla Q Goka, Onike P Rodrigues, Francis N Nkrumah, Thor G Theander, Christian Bygbjerg and Michael Alifrangis, Hansson et al Human genetic polymorphisms in the Knops blood group are not associated with a protective advantage against *Plasmodium falciparum* malaria in Southern Ghana. *Malaria*, 12:400 (2013).